Fmr LLC Gossamer Bio, Inc. Transaction History

Fmr LLC

$1.52 Trillion
Q2 2024

A detailed history of Fmr LLC transactions in Gossamer Bio, Inc. stock. As of the latest transaction made, Fmr LLC holds 7,930,508 shares of GOSS stock, worth $7.61 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

7,930,508

Previous 8,189,147 3.16%

Holding current value

$7.61 Million

Previous $9.66 Million 26.14%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$0.51 - $1.27 $131,905 - $328,471	-258,639 Reduced 3.16%	7,930,508 $7.14 Million
Q1 2024 May 13, 2024	SELL	$0.8 - $1.51 $3.26 Million - $6.15 Million	-4,074,771 Reduced 33.23%	8,189,147 $9.66 Million
Q4 2023 Feb 13, 2024	BUY	$0.48 - $1.08 $5.58 Million - $12.6 Million	11,625,497 Added 1820.98%	12,263,918 $11.2 Million
Q3 2023 Nov 13, 2023	BUY	$0.78 - $1.82 $495,200 - $1.16 Million	634,873 Added 17893.83%	638,421 $529,000
Q2 2023 Aug 11, 2023	BUY	$0.98 - $1.53 $328 - $512	335 Added 10.43%	3,548 $4,000
Q1 2023 May 11, 2023	SELL	$0.96 - $2.92 $51,033 - $155,227	-53,160 Reduced 94.3%	3,213 $4,000
Q4 2022 Feb 13, 2023	SELL	$1.74 - $12.87 $2.14 Million - $15.8 Million	-1,230,333 Reduced 95.62%	56,373 $122,000
Q3 2022 Nov 10, 2022	BUY	$7.21 - $14.88 $2.42 Million - $5 Million	335,700 Added 35.3%	1,286,706 $15.4 Million
Q2 2022 Aug 12, 2022	SELL	$5.97 - $9.97 $1,564 - $2,612	-262 Reduced 0.03%	951,006 $7.96 Million
Q1 2022 May 13, 2022	BUY	$8.44 - $12.49 $479,121 - $709,032	56,768 Added 6.35%	951,268 $8.26 Million
Q3 2021 Nov 15, 2021	BUY	$7.25 - $13.23 $6.49 Million - $11.8 Million	894,500 New	894,500 $11.2 Million

Others Institutions Holding GOSS

# of Institutions

101

Shares Held

175M

Call Options Held

453K

Put Options Held

543K

View Full List

About Gossamer Bio, Inc.

Ticker GOSS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,954,000
Market Cap $90.2M
Description
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony...

More about GOSS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fmr LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fmr LLC with notifications on news.

Account